Patents Issued in August 13, 2019
-
Patent number: 10376502Abstract: Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity.Type: GrantFiled: July 30, 2015Date of Patent: August 13, 2019Inventors: Yanming Du, Xiaodong Xu, Hong Ye, Jinhong Chang, Timothy M. Block
-
Patent number: 10376503Abstract: Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.Type: GrantFiled: March 9, 2018Date of Patent: August 13, 2019Assignee: Celgene CorporationInventors: G. Patrick Stahly, David Jonaitis, Ho-Wah Hui, Kevin J. Klopfer
-
Patent number: 10376504Abstract: The present invention is directed to azacyanoquinolinone compounds of the general structural formula: (wherein R5 and R6 are defined herein) which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: July 27, 2016Date of Patent: August 13, 2019Assignee: Merck, Sharp & Dohme Corp.Inventors: Antonella Converso, Kevin Rodzinak
-
Patent number: 10376505Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.Type: GrantFiled: December 13, 2018Date of Patent: August 13, 2019Assignee: Wyeth, LLCInventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
-
Patent number: 10376506Abstract: The present invention relates to an opioid antagonist with ?-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with ?-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with ?-activity and vortioxetine.Type: GrantFiled: December 18, 2014Date of Patent: August 13, 2019Assignee: H. LUNDBECK A/SInventors: Connie Sanchez Morillo, Gennady N. Smagin
-
Patent number: 10376507Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.Type: GrantFiled: May 16, 2017Date of Patent: August 13, 2019Assignee: BOW RIVER LLCInventors: Sundar Srinivasan, Christina Chow
-
Patent number: 10376508Abstract: Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: GrantFiled: November 22, 2017Date of Patent: August 13, 2019Assignees: ARADIGM CORPORATION, OREGON STATE UNIVERSITYInventors: Igor Gonda, James Blanchard, David C. Cipolla, Luiz Eduardo Moreira Bermudez
-
Patent number: 10376509Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprise administering to the subject in need thereof a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a clofazimine analog selected from B746 clofazimine analog or B826 clofazimine analog.Type: GrantFiled: August 22, 2018Date of Patent: August 13, 2019Assignee: KamTek, Inc.Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
-
Patent number: 10376510Abstract: Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.Type: GrantFiled: July 10, 2014Date of Patent: August 13, 2019Assignee: AGIOS PHARMACEUTICALS, INC.Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins
-
Patent number: 10376511Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.Type: GrantFiled: August 4, 2016Date of Patent: August 13, 2019Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem LTD.Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
-
Patent number: 10376512Abstract: The disclosure relates to a crystal of an aniline pyrimidine compound of trifluoroethyl substituted indole and a salt thereof as an EGFR inhibitor, specifically relates to a crystal of a compound represented by formula I, a crystal of monomethyl sulfonate of the compound represented by formula I or a crystal of dimethyl sulfonate of the compound represented by formula I, and further relates to a method for preparing the crystal, a crystalline composition comprising the crystal, or a pharmaceutical composition comprising the crystal or a crystalline composition thereof, and a medical use thereof.Type: GrantFiled: August 9, 2018Date of Patent: August 13, 2019Assignee: CHIA TAI TIANQING PHARMAEUTICAL GROUP CO., LTD.Inventors: Lulu Wang, Jianqiu Tang, Yizhong Zhu, Fei Liu, Yan Zhu, Chuanyu Zhang, Limin Yang
-
Patent number: 10376513Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.Type: GrantFiled: August 24, 2018Date of Patent: August 13, 2019Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: Richard B. Sparks, Andrew P. Combs, Brent Douty, Yun-Long Li, Song Mei, Eddy W. Yue
-
Patent number: 10376514Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: October 18, 2018Date of Patent: August 13, 2019Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael I. Weinhouse
-
Patent number: 10376515Abstract: Disclosed are analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activing enzyme ATG7. The AMP analogs may be formulated as pharmaceutical compositions for treating diseases or disorders that depend on ATG7 activity and/or autophagy such as cell proliferative diseases and disorders.Type: GrantFiled: May 2, 2017Date of Patent: August 13, 2019Assignee: NORTHWESTERN UNIVERSITYInventors: Alexander V. Statsyuk, Heeseon An
-
Patent number: 10376516Abstract: Methods for treating a hypertensive human patient are disclosed herein. A method in accordance with one embodiment comprises delivering a neuromodulatory agent to a renal nerve of the patient via an intravascularly positioned drug delivery catheter. The method includes at least partially blocking neural activity along the renal nerve with the neuromodulatory agent, which results in a therapeutically beneficial reduction in blood pressure of the patient.Type: GrantFiled: April 24, 2018Date of Patent: August 13, 2019Assignee: Medtronic Ardian Luxembourg S.a.r.l.Inventors: Mark Gelfand, Howard R. Levin
-
Patent number: 10376517Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.Type: GrantFiled: April 10, 2018Date of Patent: August 13, 2019Assignees: Madrigal Pharmaceuticals, Inc., Hoffmann-La Roche Inc.Inventors: Rebecca Taub, Charles H. Reynolds, Lianhe Shu, Ping Wang, Duk Soon Choi
-
Patent number: 10376518Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.Type: GrantFiled: March 28, 2014Date of Patent: August 13, 2019Assignee: UCL BUSINESS PLCInventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
-
Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
Patent number: 10376519Abstract: This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.Type: GrantFiled: July 31, 2017Date of Patent: August 13, 2019Assignee: G1 Therapeutics, Inc.Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Ricky D. Gaston, Robert C. Gadwood -
Patent number: 10376520Abstract: The present invention discloses compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the prophylaxis and/or treatment of cardiovascular disorders and/or dyslipidemia, by administering the compound according to Formula (I).Type: GrantFiled: March 31, 2016Date of Patent: August 13, 2019Assignee: GALAPAGOS NVInventors: Piet Tom Bert Paul Wigerinck, Gerben Albert Eleutherius Van 'T Klooster
-
Patent number: 10376521Abstract: Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.Type: GrantFiled: November 5, 2014Date of Patent: August 13, 2019Assignee: University of South FloridaInventors: Michael John Zaworotko, Heather Clarke, Arora Kapildev, Padmini Kavuru, Roland Douglas Shytle, Twarita Pujari, Lissette Marshall, Tien Teng Ong
-
Patent number: 10376522Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogs of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.Type: GrantFiled: June 6, 2016Date of Patent: August 13, 2019Assignees: Emory University, U.S. Government as Represented by the Dept. of VAInventor: Jack L. Arbiser
-
Patent number: 10376523Abstract: An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition containing: a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof, where X represents a halogen atom, and a quaternary ammonium surfactant. A method for producing an aqueous composition with an antiseptic effect, by incorporating a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof and a quaternary ammonium surfactant into the aqueous composition.Type: GrantFiled: September 25, 2015Date of Patent: August 13, 2019Assignee: KOWA COMPANY, LTD.Inventor: Shin Sugimoto
-
Patent number: 10376524Abstract: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.Type: GrantFiled: February 28, 2017Date of Patent: August 13, 2019Assignee: Emory UniversityInventors: Kathy P. Parker, David B. Rye, Andrew Jenkins
-
Patent number: 10376525Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: February 1, 2016Date of Patent: August 13, 2019Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Patent number: 10376526Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.Type: GrantFiled: September 13, 2017Date of Patent: August 13, 2019Assignee: GLENMARK SPECIALTY S.A.Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
-
Patent number: 10376527Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.Type: GrantFiled: March 15, 2018Date of Patent: August 13, 2019Assignee: DR. REDDY'S LABORATORIES LTD.Inventors: Ankit Baheti, Bijay Kumar Padhi, Supritha Vakada, Rajeev Singh Raghuvanshi
-
Patent number: 10376528Abstract: The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.Type: GrantFiled: March 10, 2017Date of Patent: August 13, 2019Assignee: TECTON GROUP, LLCInventor: Michael A. Schmidt
-
Patent number: 10376529Abstract: The present invention is related to a product comprising a pentacyclic triterpene of formula (I) and a hydroxytyrosol or derivatives thereof of formula (II), pharmaceutical compositions thereof and their uses as antioxidants, anti-inflammatories and neuron protectors.Type: GrantFiled: June 12, 2014Date of Patent: August 13, 2019Assignee: NATAC BIOTECH, S.L.Inventors: José Carlos Quintela Fernández, Esther De La Fuente García, Marco Pugliese, Pilar Mancera Aroca, Javier Bustos Santafé, Juan Francisco Espinosa Parrilla, Noemí Virgili Treserres, Blanca Wappenhans Battestini
-
Patent number: 10376530Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or therapeutic effect on Gleevec-resistant leukemia through enhancing cell killing activity of NK cells; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or ameliorating Gleevec-resistant leukemia. Since the pharmaceutical composition of the present invention can effectively treat leukemia that exhibits resistance to conventional Gleevec, the pharmaceutical composition can be widely used for effective leukemia treatment.Type: GrantFiled: May 4, 2016Date of Patent: August 13, 2019Assignee: Intelligent Synthetic Biology CenterInventors: Sun Chang Kim, Hun Sik Kim
-
Patent number: 10376531Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.Type: GrantFiled: June 29, 2018Date of Patent: August 13, 2019Assignee: Pfizer Inc.Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
-
Patent number: 10376532Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.Type: GrantFiled: October 9, 2013Date of Patent: August 13, 2019Assignee: Chiesi Farmaceutici, S.p.A.Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
-
Patent number: 10376533Abstract: The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: or a pharmaceutically acceptable salt, ester, stereoisomer, tautomers, solvate, prodrug, or combination thereof.Type: GrantFiled: December 2, 2016Date of Patent: August 13, 2019Assignee: Spring Bank Pharmaceuticals, Inc.Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
-
Patent number: 10376535Abstract: Provided herein, inter alia, are methods and compositions directed to suppressing tumor cell growth in a subject as well as methods for sensitizing a proliferating cell for treatment with a cytotoxic agent via inhibiting expression of HE4 and one or more immune checkpoint inhibitors (ICIs). Also provided herein are methods for determining whether a subject who has been diagnosed with cancer would benefit from immunotherapy as well as methods for determining whether a subject with cancer is responding to immunotherapy via assessment of levels of HE4 gene and/or protein expression.Type: GrantFiled: March 28, 2016Date of Patent: August 13, 2019Assignee: University of RochesterInventors: Richard G. Moore, Rakesh K. Singh, Naohiro Yano
-
Patent number: 10376536Abstract: An antisense oligomer capable of binding to a selected target on the ITGA4 gene transcript to modify pre-mRNA splicing in an ITGA4 gene transcript or part thereof.Type: GrantFiled: May 10, 2016Date of Patent: August 13, 2019Assignee: MURDOCH UNIVERSITYInventors: Stephen Donald Wilton, Sue Fletcher, May Aung-Htut
-
Patent number: 10376537Abstract: Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.Type: GrantFiled: August 23, 2012Date of Patent: August 13, 2019Assignee: MARINOMED BIOTECH AGInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Koller, Alexander Pretsch
-
Patent number: 10376538Abstract: Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments.Type: GrantFiled: July 18, 2017Date of Patent: August 13, 2019Assignee: Novan, Inc.Inventors: Nathan Stasko, Susanne Bauman, Pranav R. Joshi
-
Patent number: 10376539Abstract: Disclosed are methods of inhibiting progression, stabilizing and reversing amyotrophic lateral sclerosis and neuromuscular degenerative diseases including spinal muscular atrophy, by administration of xenon, or noble gas compositions at a sufficient frequency and concentration to evoke anti-inflammatory, immunomodulatory, and regenerative processes in a patient in need of therapy. In one embodiment, xenon is administered as a pharmaceutical preparation at a concentration of 5 to 90% by volume, more preferably for certain embodiments, at 5 to 30% by volume, wherein said pharmaceutical preparation additionally contains oxygen, argon, nitrogen and/or air. In other embodiments argon is utilized together, or as a replacement for xenon. Furthermore, the use of xenon and/or other noble gas combinations are disclosed for augmentation of therapies that augment endogenous regenerative cells.Type: GrantFiled: May 17, 2017Date of Patent: August 13, 2019Assignee: Nobilis Therapeutics, Inc.Inventors: Vlad Bogin, Thomas Ichim, Santosh Kesari
-
Patent number: 10376540Abstract: The invention relates to tungsten (VI) salts for use thereof in the treatment of infertility in a non-diabetic female mammal, for favoring normal reproduction and fertility in a non-diabetic female mammal, or for increasing the efficacy of an assisted reproductive technique applied to a mammal, as well as compositions containing same and methods for treatment using same.Type: GrantFiled: July 21, 2014Date of Patent: August 13, 2019Assignee: OXOLIKE, S.L.Inventors: Ignacio Canals Almazán, Agnès Arbat Bugié
-
Patent number: 10376541Abstract: There are disclosed topical silver(II) antibiotic formulations. Other embodiments are also disclosed.Type: GrantFiled: February 26, 2018Date of Patent: August 13, 2019Assignee: AIDANCE SKINCARE & TOPICAL SOLUTIONS LLCInventors: Perry Antelman, Bharat Madhavan, Shalom Lampert
-
Patent number: 10376542Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 25, 2017Date of Patent: August 13, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Anita Weibe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10376543Abstract: The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.Type: GrantFiled: March 6, 2017Date of Patent: August 13, 2019Assignee: MEGMILK SNOW BRAND CO., LTD.Inventors: Aiko Ohmachi, Hiroaki Matsuyama, Yoshikazu Morita, Yuko Ishida, Takayuki Nara, Ken Kato, Atsushi Serizawa, Hiroshi Ueno, Hiroshi Urazono
-
Patent number: 10376544Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.Type: GrantFiled: November 3, 2017Date of Patent: August 13, 2019Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITYInventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
-
Patent number: 10376545Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.Type: GrantFiled: April 3, 2017Date of Patent: August 13, 2019Assignee: ViaCyte, Inc.Inventors: Alan D. Agulnick, Kevin Allen D'Amour
-
Patent number: 10376546Abstract: Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.Type: GrantFiled: May 23, 2014Date of Patent: August 13, 2019Assignee: MiMedx Group, Inc.Inventors: Brenda S. Morse, Somaly Sith, Randall Spencer, Steven Ray, John Daniel, Robert Tofe
-
Patent number: 10376547Abstract: The present application relates to a composition consisting of honey, beeswax and cocoa butter, characterized by a melting temperature of 36±3° C., pharmaceutical, veterinary or cosmetic formulations comprising or coated by said composition, and processes for the preparation of said composition and said formulations.Type: GrantFiled: March 10, 2015Date of Patent: August 13, 2019Assignee: ABOCA S.P.A. SPCIETÀAGRICOLAInventors: Valentino Mercati, Luca Rampoldi
-
Patent number: 10376548Abstract: Compositions and methods are provided for improving the health of an animal by reducing certain diseases and by binding certain heavy metals that may be unintentionally introduced into the body of the animal from the environment. Compositions and methods are also provided for improving the feed conversion ratio of an animal. In addition, compositions and methods are provided for reducing nitrate pollution in the environment. In one embodiment, the composition may include mastic gum, a mixture of ionic minerals, and optionally an essential amino acid not produced by the animal. The ionic minerals may be derived from water sourced from an inland sea such as the Great Salt Lake, the Dead Sea, or another inland sea. The essential amino acid may be included in the form of a protein. The animal may be a ruminant, poultry, or other animal. Methods are also provided for processing mastic gum.Type: GrantFiled: October 14, 2014Date of Patent: August 13, 2019Assignee: ABSORBEZZ, LLCInventors: Joseph Scivoletto, Steven Adelstein
-
Patent number: 10376549Abstract: The present disclosure describes the generation and the use of Ad variants (Ad) possessing any combination of mutations in genes that code for the hexon, penton, fiber, and non-structural proteins, where simultaneous modification of hexon and penton are made to avoid the trapping of Ad in the liver and to reduce toxicity after intravascular virus administration. Such liver de-targeted Ad can be useful tool for selective and specific gene delivery to extra-hepatic tissues and cells, including disseminated metastatic cancer cells.Type: GrantFiled: January 17, 2016Date of Patent: August 13, 2019Assignee: ADCURE BIOTECHNOLOGIES, LLC.Inventors: Dmitry M. Shayakhmetov, Nelson C. Di Paolo
-
Patent number: 10376550Abstract: A method of modulating inflammation in an organism, which includes administering to an organism a composition including a therapeutic amount of a hydrolyzed extract from the plant Biota orientalis. Several key components of the hydrolyzed extract of Biota orientalis have been identified that have also been shown to have an effect in dramatically reducing inflammatory responses.Type: GrantFiled: April 4, 2016Date of Patent: August 13, 2019Assignee: Dacy Tech Pty Ltd.Inventor: Dan Bright
-
Patent number: 10376551Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.Type: GrantFiled: March 22, 2017Date of Patent: August 13, 2019Assignee: PIVOT NATURALS, LLCInventors: Ross M Franklin, Ed Rosenthal, Rachel M. Franklin
-
Patent number: 10376552Abstract: The present invention relates to the technical field of health food, and discloses a memory improving composition and the preparation method and use thereof. The composition is made from Arillus Longan, Poria, Semen Nelumbinis, enzymatic extract of Semen Juglandis, phosphatidylserine and taurine. In the present invention, the sovereign drug Arillus Longan is combined with ministerial drugs Poria and Semen Nelumbinis to synergistically achieve the effect of nourishing heart for tranquillization and tonifying kidney & invigorating spleen. They are further combined with enzymatic extract of Semen Juglandis improving brain metabolism and enhances memory, functional factor phosphatidylserine increasing fluidity and enhances plasticity of cell membrane, and taurine improving memory, to achieve the purpose of memory improvement together.Type: GrantFiled: August 31, 2016Date of Patent: August 13, 2019Assignee: INFINITUS (CHINA) COMPANY LTD.Inventors: Yong Zhou, Xiaolei Guo, Chung Wah Ma